SAN FRANCISCO, Jan. 8 - Transgenomic has entered into an agreement with privately held functional genomics firm GenOdyssee to market and sell nucleic acid analysis services around the world that will be performed by a unit of GenOdyssee, Transgenomic said at a healthcare conference here on Tuesday.
"We have repeatedly encountered the need for analysis services from prospective customers," Collin D'Silva, Transgenomic's chairman and CEO, said in a statement that release after his presentation at the 20th annual JPMorgan H&Q Healthcare Conference, held here through Thursday. "We have been impressed with the capabilities GenOdyssee has developed in part with our WAVE fragment analysis system."
Added the unit, GenOdyssee Genetics, the alliance with Transgenomic will give it access "to a much broader market, and in particular to the US market."
The territory covered by the agreement includes the United States, the European Union, the United Kingdom, Switzerland, and Japan. Users of the services will include biopharmaceutical companies seeking to establish ties between genetic variation and phenotypic activity and to identify drug targets, Transgenomic said.
GenOdyssee, based in France, has owned and operated what it considers to be the largest HTS platform of Transgenomic's WAVE systems in Europe.
"In order to maximize the platform capacity and quality, we have developed and protected a multiplexing method that allows us to reach the high throughput screening scale using the WAVE systems and a proprietary LIMS that controls the platform performance, and allows us to do data integration in real time," GenOdyssee Genetics said.